Mumbai, Dec. 15 -- Bioconannounced the launch of its GLP-1 peptide, Liraglutide, for diabetes (gVictoza(R)) and obesity (gSaxenda(R)), in the Netherlands through its distribution partner Pharmamedic B.V. The drug-device combination will be marketed in the Netherlands under the brand names Diavorin(R) for diabetes and Vobexoryn(R) for chronic weight management.

Published by HT Digital Content Services with permission from Capital Market....